Arcellx (NASDAQ:ACLX) Announces Earnings Results, Meets Estimates

Arcellx (NASDAQ:ACLX) released its earnings results on Thursday. The company reported ($1.01) earnings per share for the quarter, meeting the consensus estimate of ($1.01), FiscalAI reports. Arcellx had a negative return on equity of 51.13% and a negative net margin of 607.01%.The company had revenue of $1.65 million for the quarter, compared to the consensus estimate of $13.40 million.

Arcellx Price Performance

Shares of ACLX stock traded up $0.12 during mid-day trading on Thursday, hitting $113.88. The company had a trading volume of 11,617,048 shares, compared to its average volume of 2,676,067. The stock’s 50 day moving average price is $69.82 and its 200-day moving average price is $75.65. Arcellx has a 52-week low of $47.86 and a 52-week high of $114.26. The company has a market capitalization of $6.58 billion, a P/E ratio of -28.98 and a beta of 0.36.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. HC Wainwright downgraded Arcellx from a “buy” rating to a “neutral” rating and set a $115.00 price objective on the stock. in a research note on Monday. William Blair lowered shares of Arcellx from a “strong-buy” rating to a “hold” rating in a report on Monday. Evercore set a $115.00 price target on shares of Arcellx in a report on Monday. UBS Group lowered shares of Arcellx from a “buy” rating to a “neutral” rating and upped their price target for the stock from $100.00 to $115.00 in a research report on Tuesday. Finally, Wells Fargo & Company cut shares of Arcellx from an “overweight” rating to an “equal weight” rating and set a $115.00 target price on the stock. in a research note on Monday. One investment analyst has rated the stock with a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $111.87.

Insiders Place Their Bets

In other Arcellx news, insider Christopher Heery sold 7,437 shares of Arcellx stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $65.51, for a total value of $487,197.87. Following the sale, the insider directly owned 29,631 shares in the company, valued at approximately $1,941,126.81. The trade was a 20.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 19,450 shares of company stock worth $1,283,477 over the last three months. Company insiders own 8.35% of the company’s stock.

Institutional Investors Weigh In On Arcellx

Several large investors have recently made changes to their positions in ACLX. State of Wyoming bought a new position in Arcellx during the second quarter valued at approximately $28,000. US Bancorp DE raised its holdings in shares of Arcellx by 57.2% during the 3rd quarter. US Bancorp DE now owns 1,797 shares of the company’s stock worth $148,000 after acquiring an additional 654 shares in the last quarter. Man Group plc bought a new position in shares of Arcellx during the 4th quarter valued at approximately $217,000. Sei Investments Co. purchased a new position in shares of Arcellx in the third quarter valued at $238,000. Finally, Virtus Investment Advisers LLC increased its position in Arcellx by 116.3% in the fourth quarter. Virtus Investment Advisers LLC now owns 3,701 shares of the company’s stock worth $241,000 after purchasing an additional 1,990 shares during the last quarter. 96.03% of the stock is owned by institutional investors.

Key Headlines Impacting Arcellx

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Heavy trading and momentum: Shares are trading with much higher-than-normal volume and are near a 52-week high, suggesting momentum, investor interest, or short-covering as a key driver. Read More.
• Neutral Sentiment: FY2030 earnings forecast released by HC Wainwright — the note provides updated forward estimates but the publicly available summary doesn’t point to a clear directional catalyst; investors should read the full note for assumptions. Read More.
• Neutral Sentiment: Short-interest data shown in the feed is inconsistent/zeroed (reported as 0 shares and NaN change); unreliable short-interest reporting makes it hard to quantify squeeze risk from these figures alone. (Internal trading/short data entry)
• Negative Sentiment: UBS downgraded ACLX — another analyst cut that increases selling pressure and raises questions about near-term expectations. Read More.
• Negative Sentiment: Citigroup downgraded ACLX — part of a cluster of big-shop downgrades that can weigh on sentiment and liquidity for the stock. Read More.
• Negative Sentiment: Multiple firms have cut ratings to Hold (Robert W. Baird, Canaccord Genuity, Needham, Wells Fargo, Evercore, Leerink Partners), signaling a broad pullback in sell-side conviction that could limit further upside until new fundamental data arrives. Read More. Read More. Read More. Read More. Read More.

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.